Alitair and Edmond announce licenses agreement for Erdosteine as

Orphan Drug Candidate in the U.S.

MORRISTOWN, New Jersey – September 26th, 2013 – Alitair Pharmaceuticals, Inc., today announced that it has entered into a definitive agreement to license Erdosteine, a mucolytic with antibacterial, anti-inflammatory, and antioxidant properties, from Edmond Pharma Srl for development as an orphan drug in the United States and Canada. Financial terms of the agreement were not disclosed.

Alitair President and CEO William Howard said, “We are delighted to have licensed Erdosteine from Edmond. Erdosteine is currently approved in 30 countries for the treatment of chronic bronchitis and chronic obstructive pulmonary disorder, or COPD. Erdosteine is also approved in 4 countries to treat bronchiectasis, which is characterized by hyper secretion of mucus. Licensing Erdosteine as a second orphan drug candidate further strengthens Alitair’s position in the respiratory arena, and we believe Erdosteine can be used concomitantly with our next generation xanthine orphan drug candidate, ALT-07, to treat both CF- and non-CF bronchiectasis.”

Roberto Teruzzi, Corvette CEO (Holding Company controlling Edmond Pharma) and Edmond Pharma President and CEO, reported: “We at Edmond Pharma are very excited about the agreement signed with Alitair. Erdosteine was discovered years ago in our R&D Labs in Italy and it is successfully distributed in several markets since a few years. It is a very safe and effective drug with a unique pharmacological profile. We are very confident that thanks to the cooperation with our partner, Erdosteine is going to play an important role in the bronchiectasis treatment.

About Alitair Pharmaceuticals:
Alitair Pharmaceuticals, Inc. is a clinical stage company that discovers, invents, and develops medicines for the treatment of respiratory illnesses. Alitair has out-licensed two prescription cough candidates that use its proprietary ion-exchange resin technology, REA™. Other product candidates are available for out-licensing. Additional information about Alitair is available on the Alitair website at www.alitair.com.

About Edmond Pharma Srl:
Edmond Pharma operates in three distinct business areas: active pharmaceutical ingredient (API) supply, finished products, and Erdosteine. The majority of Edmond’s API business is devoted to export. Edmond Pharma manufactures oral solid finished products which are sold worldwide, and the company discovered and developed Erdosteine as a new chemical entity (NCE). Today the product is registered in 43 countries worldwide for respiratory diseases including Copd. Find out more at www.edmondpharma.com and www.erdosteine.net.

About Orphan Drug Status
Orphan drug designations are granted by the FDA's Office of Orphan Products Development for treatments that are expected to provide significant therapeutic advantage over existing treatments and that target conditions affecting 200,000 or fewer U.S. patients per year. Receiving an orphan drug designation qualifies a company for several benefits under the Orphan Drug Act of 1983. The benefits apply across all stages of drug development and include accelerated approval process;
seven years of market exclusivity following marketing approval; tax credits on U.S. clinical trials; eligibility for orphan drug grants; and waiver of certain administrative fees.

###

Source: Alitair Pharmaceuticals, Inc.
www.alitair.com

Contact: Faith Pomeroy-Ward
Vice President, Corporate Development
505-780-5472 | faith@alitair.com

Source: Edmond Pharma S.r.l.
www.edmondpharma.com

Contact: Pierfrancesco Manzo
Erdosteine Sales and Business Development Director
+39 02.95.00.46.283 | p.manzo@edmondpharma.it